ALEC · CIK 1653087
What Alector, Inc. told the SEC could break it.
Alector's disclosures are those of a pre-revenue drug developer whose risks concentrate in single points of failure. Most of its operations — corporate headquarters and roughly 105,000 square feet of R&D labs — sit in one South San Francisco facility exposed to earthquake, fire and other single-site interruption, and on the supply side it has no long-term supply agreements and depends on limited or sole-sourced raw materials to make its product candidates. With a $972.1 million accumulated deficit and no product revenue, it has pledged a first-priority security interest on substantially all of its assets under its loan agreement, and it flags the Inflation Reduction Act's Medicare price-negotiation and rebate provisions as a hazard for any product it eventually commercializes.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Geographic concentration
- single South San Francisco, CA headquarters/labmedium
The majority of operations, including corporate HQ and R&D labs (~105,000 sq ft), are concentrated in one South San Francisco facility, exposing the company to earthquake, fire and other single-site interruption risk.
“The majority of our operations including our corporate headquarters are located in a facility in South San Francisco, California.”
SEC filing →As of 2026
Liquidity & debt
- secured term loan; $972.1M accumulated deficit, no product revenuemedium
With a $972.1M accumulated deficit and no product revenue, Alector has pledged a first-priority security interest on substantially all assets under its Loan Agreement and may be unable to arrange additional financing.
“As security for our obligations under the Loan Agreement, we granted the collateral agent a first priority security interest on substantially all of our assets, subject to certain exceptions.”
SEC filing →As of 2026
Regulatory & policy
- Inflation Reduction Act drug-price negotiation and rebatesmedium
The Inflation Reduction Act of 2022 lets the federal government negotiate maximum fair prices for high-priced single-source Medicare drugs, imposes inflation rebates and penalties — material implications for Alector's future commercialized products.
“In August 2022, Congress passed the Inflation Reduction Act of 2022, which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs”
Sole-source dependency
- limited/sole-sourced raw materials for drug productmedium
Alector has no long-term supply agreements and buys drug product on a purchase-order/development-services basis; interruption in limited or sole-sourced raw materials could halt manufacture of its product candidates.
“Any supply interruption in limited or sole sourced raw materials, including those caused by the effects of worldwide economic conditions including pandemics and other public health outbreaks, geopolitical events, export or import restrictions, or trade tariffs, could materially harm our ability to manufacture our product candidates unti”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“Our revenue to date has been primarily related to the AbbVie Agreement and GSK Agreement for the license and co-development of product candidates with those parties.”
Cited →“Our revenue to date has been primarily related to the AbbVie Agreement and GSK Agreement for the license and co-development of product candidates with those parties.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch